Ubs Group Ag Aquestive Therapeutics, Inc. Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
A detailed history of Ubs Group Ag transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 314,329 shares of AQST stock, worth $1.07 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
314,329
Previous 420,563
25.26%
Holding current value
$1.07 Million
Previous $1.49 Million
38.78%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding AQST
# of Institutions
129Shares Held
44.5MCall Options Held
44.6KPut Options Held
182K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$33.4 Million100.0% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$18.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.07MShares$13.9 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.73MShares$12.7 Million0.45% of portfolio
-
Geode Capital Management, LLC Boston, MA1.7MShares$5.78 Million0.0% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $181M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...